subject: Pipeline And Commercial Insight: Schizophrenia - Opportunity Remains Beyond Positive Symptoms [print this page] Introduction Introduction
Despite imminent generic erosion of blockbuster brands, the schizophrenia market will retain its value, supported by the uptake of premium priced depot formulations and new pipeline therapies to offset the loss in sales revenue. Datamonitor forecasts the schizophrenia market to grow at a compound annual growth rate of 1.0% (20092019).
Features and benefits
Analysis of current schizophrenia treatment approaches and drug recommendations, patient acquisition process and unmet medical needs.
In depth analysis of historic (200509) and future (20102019) seven major market sales dynamics.
Review of the schizophrenia drug pipeline dynamics, including detailed profiles of key late-stage products.
Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019.
Highlights
Despite the success of the atypical antipsychotics, several major unmet needs remain, including improved patient compliance, solutions for partial responders or treatment refractory patients, improved treatment of cognitive and negative symptoms and therapies with an enhanced side-effect profile.
In the face of increasing cost constraints and competition in the schizophrenia market stemming from the genericization of atypical antipsychotics, Datamonitor does not expect new undifferentiated pipeline products to be positioned as first-line therapies or replicating the success of the current leading atypical antipsychotics.
With current treatment options only exhibiting strong efficacy for positive symptoms, the opportunity remains for developers to address the lucrative patient population suffering from negative and cognitive impairment.
Your key questions answered
Quantify the current and future size of the schizophrenia market.
Identify potential licensing opportunities based on product portfolios and anticipated market needs.
Understand the country-specific impact of key events in the schizophrenia market during the forecast period 2010 to 2019.
